Passage BIO, Inc. — Director's Dealing 2023

Apr 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2023-04-18

Reporting Person: King Simona (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-18	Common Stock	M	6250	$0.00	Acquired	6250	Direct
2023-04-18	Common Stock	S	2053	$1.05	Disposed	2053	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-04-18	Restricted Stock Units	$	M	6250	Disposed		Common Stock (6250)	Direct

Footnotes

F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.

F3: 1/4 of the RSUs vested on April 18, 2023, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F4: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.